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Editorial on the Research Topic
TheWarburg Effect Regulation Under Siege: the Intertwined Pathways in Health and Disease
In the 1920s, the biochemist Otto Warburg observed that, unlike normal cells, cancer cells
catabolize glucose into lactate under aerobic conditions (hence the name “The Warburg Effect”
or aerobic glycolysis) (Warburg et al., 1927). For eight decades, the Warburg’s observation was
almost ignored, as only limited evidence indicated that aerobic glycolysis is characteristic of nearly
all types of cancer. Over the last decade, with the development of modern analytical tools, we
have witnessed a resurgence of interest in the study of the Warburg effect and the mechanistic
basis of its occurrence in cancer. Not surprising, Hanahan and Weinberg (2011) in their revised
list of “Hallmarks of Cancer” have included the Warburg effect as an emerging hallmark of
cancer. More recently, however, a plethora of detailed investigations have also revealed crucial
roles for the Warburg effect in a number of homeostatic processes, including high cell turnover
and proliferation, immune responses, and brain development. To highlight the importance of the
Warburg effect in health and disease, we are delighted to introduce our Research Topic containing
a diversity of Review and Research Articles that will discuss the ground-breaking discoveries and
advances in the field.
The Research Topic covers progress in understanding the role of the Warburg effect in cancer,
immunity, inflammation, atherosclerosis, angiogenesis, and tissue homeostasis. The collection of
articles in this Research Topic represents a valuable platform where theWarburg Effect is discussed
from different perspectives, including how intrinsic and extrinsic regulatory pathways control
aerobic glycolysis in normal and diseased conditions, and appropriately discusses the molecular
basis for its inhibition in an array of human diseases.
The opening article of our Series is the detailed review by Wiese and Hitosugi that summarizes
the complex role and regulation the key driver of Warburg effect, the pyruvate kinase M2 isoform
(PKM2), in different cell types. The pyruvate kinase (PK) is a homotetrameric glycolytic enzyme
that exists in mammals as four isoforms (PKL, PKR, PKM1, and PKM2) with different expression
patterns. Its enzymatic activity catalyses the conversion of phosphoenolpyruvate (PEP) to pyruvate.
The authors highlight the paradox that unlike other glycolytic enzymes, for which it is required an
elevated expression and activity, PKM2 catalytic activity has to be maintained down to promote the
Warburg effect in cancer cells. Indeed, it has been proposed that low PKM2 activity allows PEP and
upstream glycolytic intermediate to accumulate and flow to anabolic pathways; when its activity
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is elevated the upstream glycolytic intermediate flow to
form pyruvate, which is then converted to lactate or enters
mitochondria for complete oxidation. Other than the allosteric
regulation by glycolytic intermediates, post-translational
modifications alter the protein localization, enzymatic activity,
and stability of PKM2 to promote the Warburg Effect. Above
all, tyrosine phosphorylation of PKM2 (i.e., Tyr105) by Tyrosine
Kinases results in decreased PKM2 activity, and this decrease
promotes the Warburg Effect (Hitosugi et al., 2009; Wiese and
Hitosugi). On the other hand, it has been shown that threonine
phosphorylation (i.e., Thr365) via c-Jun N-terminal Kinase
(JNK) results in increased PKM2 activity and consequential
apoptosis of cancer cells (Iansante et al., 2015; Papa et al., 2019),
highlighting the necessity for highly proliferating cancer cells to
preserve low PKM2 activity. The authors highlight the complex
role of PKM2 with anti- and pro-tumorigenic function in cancer
development depending on cancer type.
By employing population and single cell time-lapse imaging
approaches, Lucantoni et al. demonstrate that the dual inhibition
of glycolysis and mitochondrial respiration increase cell death
and decrease clonogenic capacity of breast cancer cells.
Importantly, it was shown that the treatment of breast cancer
cells with the mitochondrial fission inhibitor MDIVI-1 alone
increases aerobic glycolysis while had no effect on mitochondrial
morphology. Suppressing the MDIVI-1-mediated increased
glycolysis with 2-deoxy-D-glucose (2-DG)—a derivative of
glucose that serves as a glycolytic inhibitor—resulted in a
synthetical lethal effect in breast cancer cells.
In another research article focusing on liver cancer, Lee
et al. show that glycolytic enzymes involved in glycolysis
and mitochondrial oxidative metabolism (OXPHOS) are highly
expressed in livers of patients with hepatocellular carcinoma
(HCC) compared to healthy livers, suggesting that glycolysis
cooperates with OXPHOS to sustain fast cellular proliferation in
HCC. The authors also show that, like HCC, aerobic glycolysis
is increased in livers of patients with cirrhosis, a chronic
inflammatory liver condition predisposing to the development of
HCC. However, in contrast to a general increase in expression
levels of genes involved in glycolysis, OXPHOS genes remained
at the same level to healthy livers in cirrhotic livers. This suggests
aerobic glycolysis may represent a marker for early detection
and chemoprevention of HCC. The authors also highlight the
fact that aerobic glycolysis is not only a distinctive phenotype
of tumors but is involved in pre-malignant conditions. A
review article by Hou and Syn provides an in-depth view of
the metabolic changes that occur during hepatic fibrogenesis,
highlighting the impact of the Warburg effect in the activation of
hepatic stellate cells such as the transdifferentiation of quiescent
perisinusoidal liver resident cells into proliferative, contractile,
and fibrogenic cells that is the core of liver fibrosis, which drives
the progression of chronic liver diseases toward liver cirrhosis
and hepatic failure.
Changes in glycolytic and mitochondrial metabolism have
an impact on the skeletal muscle fiber composition and are
reviewed by Julien et al. in this issue. The authors describe
the metabolic characteristic of muscle fibers and evaluate the
metabolite-dependent intracellular pathways that influence fiber
composition. In particular, the authors discuss that during
extensive exercise a rapid increase of glycolysis occurs in skeletal
muscle fibers and pyruvate is converted to lactate, reminiscent
of the Warburg effect in cancer cells. This metabolic swift is
under control of specific metabolite-dependent cell signaling
and transcriptional programs. A better understanding of these
programs may facilitate therefore the therapy progress against
aging and neurodegenerative diseases like amyotrophic lateral
sclerosis, Huntington’s disease, and Alzheimer’s disease.
We were also thrilled to read a review article by Theodorou
and Boon discussing the role of glucose, fatty acid, and amino
acid metabolism in endothelial cells in response to various
physiological and pathological stimuli. Their report suggests that
interfering with the glycolytic metabolism in endothelial cells
may provide therapeutic strategy for atherosclerosis, even in the
presence of risk factors such as diabetes and obesity. In support
of this idea, Fitzgerald et al. review how changes in endothelial
cell metabolism affect endothelial cell fate during physiological
sprouting, as well as during angiogenesis. Targeting metabolism
in endothelial cells may have therapeutic potential for pathologies
associated with angiogenesis such as cancer.
Metabolic pathways have also been implicated in the
differentiation and activation of immune cells. Salmond reviews
how the mechanistic target of rapamycin (mTOR) pathway
regulates the metabolic reprogramming of specialized helper T
cell (Th) subsets and discusses the role of glycolytic metabolism
in T cell subsets. While the differentiation and effector functions
of inflammatory Th1, Th2, and Th17 cells relies on engagement
of aerobic glycolysis where mTOR signals play a key role in
these processes, memory T cells and Tregs are dependent on
fatty acid oxidation pathways. Although it was believed that
compared to resting dendritic cells (DCs), activated DCs possess
only increased glycolytic metabolism, Du et al. review recent
progress in understanding the metabolic changes occurring
in different DC subsets and outstanding questions in the
field. The review article by Sieow et al. provides an overview
on how myeloid cells undergo metabolic reprogramming in
the tumor microenvironment and covers implications for
cancer immunotherapies.
Following these articles on the Warburg effect, Rosenzweig
et al. report a very interesting review article discussing a new
perspective that goes beyond the Warburg effect. In particular,
they describe how the one-carbon metabolism is regulated in
cancer and normal proliferating cells. One-carbon metabolism
supports multiple physiological processes that include nucleotide
biosynthesis, amino acid homeostasis, methylation, and redox
defense. The authors argue that one-carbon metabolism is
therefore an essential integrator of the nutritional status of
proliferating cells that serves as building blocks for biosynthesis,
epigenetic, and redox reactions, and discuss how dysregulated
oncogenic signals control these metabolic pathways to support
and sustain high rates of proliferation and cell survival essential
for tumor growth.
As the implications of the Warburg effect in health and
disease continue to emerge, we are entering into a renaissance
period for metabolism research. Since the Warburg’s original
observation, we have learnt a lot about the effect of signal
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transduction on metabolic pathways and how cells rapidly
reprogram their metabolism although much remains to
be discovered.
This Research Topic has attracted two original research
articles and a considerable number of remarkable review articles
providing a comprehensive view of the current knowledge on the
molecular pathways and regulation of the Warburg effect and
its implications in homeostasis and pathology and relevance in
translational research.
We thank all authors and referees for their contributions
in producing this special collection. Last but not least,
we thank the Frontiers Editorial Office and the Journal
Development Team for their dedication and work that made this
Research Topic possible.
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